Mediclinic International is aware of a fake social media post that is being circulated requesting users to engage with a Medical Feedback Reward Survey. Mediclinic has not circulated any such survey. The social media post has not been published by Mediclinic. Mediclinic advises that people do not engage with the survey or respond. We release all our official communications on our website and our official social media channels.
GI malignancies including colon cancer, pancreatic cancer and gastric/esophageal malignancies
Melanoma
Lymphoma
Gynaecological malignancies including endometrial cancer, ovarian cancer and cervical cancer
Lung cancer
Urological malignancies including bladder cancer , renal cancer and prostate cancer
Targeted therapies across solid tumor types
Profile
Nationality
UAE national
Summary
Shaheenah Dawood is a consultant medical oncologist and professor in Clinical Oncology in the United Arab Emirates with nearly 20 years of experience having worked in Canada, USA and UAE.
She was the head of the Medical Oncology program at the Dubai Health Authority for nearly a decade prior to moving to Mediclinic. She trained in Medical Oncology at McGill University Hospitals in Montreal, Canada, and then did the Susan Komen Breast Cancer fellowship at the MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of Medicine and has a Masters of Public Health from the Harvard School of Public Health. She has, in addition, graduated from the American Society of Clinical Oncology Society leadership development program from the USA.
She has been actively involved in research and has played a key role in developing the cancer research program in the UAE. She has over 100 publications to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals. She is currently the head of the Oncology research program at Mediclinic City Hospital, Dubai, and is working closely with the Mohammed Bin Rashid University of Medicine and Health Sciences to develop the Oncology research program across a range of solid tumour types and is actively developing the clinical trials program with the goal of increasing accessibility of novel agents to our patients in the UAE.
She also serves as president of the Excellence in oncology summit that is held annually in Dubai and is co-president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS) and the precision oncology forum. She has also recently launched the international BRCA forum and young womens forum. She currently serves on multiple committees at the Amercian Society of Clinical Oncology and European Society of Medical Oncology.
She manages a range of solid tumours and is a member and leads multiple local and international multidisciplinary tumour boards. She is actively leading the precision oncology initiative at an international level across solid tumour types and has been awarded the Emirati contributor award for her work in the field of precision oncology. She has introduced a range of targeted therapies to Mediclinic, making it the first institution across the Gulf to use innovative medications such as pembrolizumab, amivantamab and entrectinib, which has served to improve prognostic outcomes for patients.
